S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
pixel
pixel
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Ergomed plc (ERGO.L)AltimmuneSilence Therapeutics plc (SLN.L)
SymbolLON:ERGONASDAQ:ALTLON:SLN
Price Information
Current PriceGBX 1,050$13.32GBX 534
52 Week RangeN/ABuyBuy
MarketRank™
Overall Score0.61.91.0
Analysis Score0.03.52.5
Community Score3.13.92.6
Dividend Score0.00.00.0
Ownership Score0.01.70.0
Earnings & Valuation Score0.00.60.0
Analyst Ratings
Consensus RecommendationN/ABuyBuy
Consensus Price TargetN/A$22.75GBX 605
% Upside from Price TargetN/A70.80% upside13.30% upside
Trade Information
Market Cap£511.56 million$440.51 million£444.86 million
BetaN/A1.51N/A
Average Volume109,3591,270,984305,133
Sales & Book Value
Annual Revenue£73.46 million$5.80 million£1.39 million
Price / Sales6.9675.95320.04
CashflowGBX 63.42 per shareN/AGBX 61.49 per share
Price / Cash16.56N/A8.68
Book ValueGBX 90.60 per share$2.97 per shareGBX 33.40 per share
Price / Book0.124.480.16
Profitability
Net IncomeN/A$-20,520,000.00N/A
EPSGBX 12.50($0.98)GBX (28.10)
Trailing P/E Ratio84.00N/AN/A
Forward P/E Ratio23.37
P/E GrowthN/AN/AN/A
Net MarginsN/A-659.33%N/A
Return on Equity (ROE)N/A-46.39%N/A
Return on Assets (ROA)N/A-38.32%N/A
Dividend
Annual PayoutN/AN/AN/A
Dividend YieldN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/A
Payout RatioN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/A
Debt
Debt-to-Equity Ratio48.12%N/A0.05%
Current Ratio1.44%34.66%9.82%
Quick Ratio1.40%34.66%9.60%
Ownership Information
Institutional Ownership PercentageN/A66.22%N/A
Insider Ownership PercentageN/A2.70%N/A
Miscellaneous
Employees8502546
Shares Outstanding48.72 million33.07 million83.31 million
Next Earnings DateN/A3/26/2021 (Estimated)N/A
OptionableNot OptionableOptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.